key: cord-0779284-sxmlbsuw
authors: Song, Dan; Liu, Jiayao; Xu, Wenjuan; Han, Xiangzhi; Wang, Hongliang; Cheng, Yuan; Zhuo, Yuxin; Long, Feng
title: Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor
date: 2021-08-14
journal: Talanta
DOI: 10.1016/j.talanta.2021.122800
sha: 824149dc473dd2b692a00df1f48987af77310a6a
doc_id: 779284
cord_uid: sxmlbsuw

The COVID-19 pandemic brings unprecedented crisis for public health and economics in the world. Detecting specific antibodies to SARS-CoV-2 is a powerful supplement for the diagnosis of COVID-19 and is important for epidemiological studies and vaccine validations. Herein, a rapid and quantitative detection method of anti-SARS-CoV-2 IgG antibody was built based on the optofluidic point-of-care testing fluorescence biosensor. Without complicated steps needed, the portable system is suitable for on-site sensitive determination of anti-SARS-CoV-2 IgG antibody in serum. Under the optimal conditions, the whole detection procedure is about 25 min with a detection limit of 12.5 ng/mL that can well meet the diagnostic requirements. The method was not obviously affected by IgM and serum matrix and demonstrated to have good stability and reliability in real sample analysis. Compared to ELISA test results, the proposed method exhibits several advantages including wider measurement range and easier operation. The method provides a universal platform for rapid and quantitative analysis of other related biomarkers, which is of significance for the prevention and control of COVID-19 pandemic.

As an astounding pandemic outbreak in the 21 st century, the coronavirus disease 2019 has caused unprecedented public health crisis and social burden all over the world [1] [2] [3] . Rapid and accurate diagnostic solutions are particularly important for the prevention and control of the overall epidemic situation [4, 5] . At present, the two main forces of diagnostic tests for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are nucleic acid detection and specific antibody detection [6, 7] . Nucleic acid detection plays an irreplaceable role in the diagnosis of COVID-19, and the real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay is regarded as the gold standard. The RT-PCR testing is an effective way for the identification of positive persons in the early stages and the large-scale population screening. However, PCR testing has several limitations, including expensive instrument, high false-negative rates, cumbersome operation, and technical personnel [6, 8] . Besides, nucleic acid detection is difficult to be applied for the identification of disease stages, past infection, and immunity situation.

Serological testing of the SARS-CoV-2 specific antibodies is a powerful supplement for the diagnosis of COVID-19 [9] [10] [11] . After SARS-CoV-2 infection, immunoglobulin M (IgM) and immunoglobulin G (IgG) is detectable at 3~6 days and 7~14 days, respectively. Therefore, antibody detection is not only useful for finding out the past infection and screening asymptomatic patients, but also for determining different infection stages [12, 13] . Compared with nucleic acid detection, antibody detection has higher sensitivity and specificity, shorter turnaround time, lower cost and technical requirement, lower risk of medical staff infection, and is more suitable for the on-site detection. Studies demonstrated that supplementing antibody detection could effectively improve accuracy of the diagnosis [14] . Currently, the serological testing methods of COVID-19 include lateral flow immunoassays (LFIA), chemiluminescence immunoassay (CLIA), and enzyme-linked immunosorbent assay (ELISA) [4, 15, 16] . LIFA is a cost-effective, fast and simple analytical testing has been demonstrated from the rapid detection of cholylglycine (CG) in serum [24] .

However, the employed indirect competitive immunoassay mechanism is not suitable for the detection of large molecules such as antibodies. Herein, based on sandwich immunoassay principle, the rapid and sensitive on-site detection method of anti-SARS-CoV-2 IgG antibody in serum was built using the OPOCT. The receptor binding domain (RBD) of spike protein (S-protein) of SARS-CoV-2 was immobilized on the fiber biosensor to regarded as the capture probe, which had been widely applied in serological detection of COVID-19 [12, 25] . When the sample containing anti-SARS-CoV-2 IgG antibody was introduced over the fiber biosensor, some of them specially bound with the spike protein. The fluorescence-labeled secondary antibody of a certain concentration was added as the fluorescence signal reporter. The higher concentration of anti-SARS-CoV-2 IgG antibody allowed more of them and more fluorescence-labeled secondary antibody bound to the fiber biosensor surface, thus resulting in the higher fluorescence intensity. According to the linear relationship between anti-SARS-CoV-2 IgG antibody concentration and fluorescence intensity, the anti-SARS-CoV-2 IgG antibody in serum can be quantified in about 25 min with simple dilution.

The recombinant RBD, anti-SARS-CoV-2 S-protein IgG calibrator, anti-SARS-CoV-2 Sprotein S IgM calibrator, Alexa Fluor 680 labelled goat anti-human IgG secondary antibody, MERS-CoV-2 antibody, HCoV-HKU1 CoV antibody were purchased from Beijing Biodragon Immunotechnologies CO., Ltd. (Beijing, China). The IgG consists of three human monoclonal antibodies that can specifically recognize SARS-CoV-2 spike protein, and the binding affinities (Kd) are 0.06 nM, 0.1 nM, 1.2 nM, respectively. Cardiac troponin I (cTnI) was purchased from Kitgen Biotechnology Co., Ltd (Zhejiang, China). Programmed cell death 1 ligand 1 (PD-L1) was purchased from Cusabio Technology Co., Ltd (Wuhan, China). Bovine serum albumin (BSA), 3mercaptopropyl-trimethoxysilane (MTS), and N-(4-maleimidobutyryloxy) succinimide (GMBS) were purchased from Sigma-Aldrich (Steinheim, Germany). All other reagents, unless specified, were of analytical grade and supplied by the Beijing Chemical Agents (Beijing, China). The phosphate-buffered saline solution (10 mM PBS, containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4, pH=7.4) and antibody dilution buffer (0.1% BSA in PBS) were prepared, respectively. The regeneration solution was 0.5% sodium dodecyl sulfate (SDS, pH = 1.9).

To detect the S-IgG antibody, the functional fiber biosensor was prepared according to previous methods [26] . In brief, fiber optic with diameter of 600 μm and length of 5.5 cm (NA=0.22) was J o u r n a l P r e -p r o o f used to prepare biosensor. To improve the excitation efficiency of evanescent wave and collection efficiency of fluorescence, the distal end of fiber optic was tapered through by HF acid tube-etching method to form a taper sensing region with length and diameter of 3.0cm and 220 μm. The sensing region was initially immersed in piranha solution (H2SO4/H2O2=3:1) to activate the hydroxyl groups for 30 min. Then, the thiol groups were introduced onto the fiber biosensor surface by placed it in 2% MTS solution (v/v in ethanol) for 2 h. After washed three times with ethanol and dried in N2, the fiber biosensor was immersed in GMBS solution for 1 h. Next, the fiber biosensor was placed in RBD solution (0.5 mg/mL) overnight in refrigerator (4 ℃). During this process, the RBD was covalently linked to the biosensor surface. Finally, the fiber biosensor was placed in BSA solution (2 mg/mL) for 2 h to blocked up nonspecific adsorption sites. The as-prepared fiber biosensor was placed at 4 °C for use.

A detailed description of the OPOCT can be found in our previous publications [26] . The platform is composed of four parts including optical module, fluidics module, electronic control module and data treatment module (Fig.S1 ). The system possesses some prominent characteristics including low cost, compact structure, high reliability and portability.

Using OPOCT platform, the immunosensing mechanism for S-IgG based on sandwich assay was illustrated in Fig. 1a . The RBD functionalized fiber biosensor was placed in optofluidic cell.

When the excitation light is introduced into the fiber biosensor, it transmits via total internal reflection (TIR) and the evanescent wave generates on the fiber biosensor surface, which has a limited penetrated depth (typically < 100 nm). First, the PBS solution was pumped over the biosensor surface, and the baseline signal (Ib) was recorded by the OPOCT (phase I in Fig.1b) .

Second, samples containing various concentrations S-IgG were introduced into the optofluidic cell and incubated for a certain time (phase II in Fig.1b) . During this period, S-IgG specifically bound with RBD immobilized onto fiber optic surface. Third, the fiber biosensor was rinsed with PBS again to remove the excess S-IgG (phase III in Fig.1b) . Fourth, the fluorescently-labeled secondary antibodies were delivered into the cell and incubated for several minutes (phase IV in Fig.1b) .

During this process, secondary antibodies bound with S-IgG on the biosensing surface, and the fluorescence was excited by evanescent wave generated on the fiber biosensor surface. Part of the fluorescence coupled back into the fiber biosensor and was real-time detected by the OPOCT.

With increasing the S-IgG concentration, the more fluorescence labeled secondary antibodies bound on the fiber biosensor surface and the higher fluorescence intensity (If) was detected. The net fluorescence signal (Is) of sample was calculated according to eq.1

The proportional relationship between Is and the S-IgG concentration in the samples was used for determination of dose-response curve. Finally, the fiber biosensor was regenerated with 0.5% SDS solution (pH=1.9) to remove the S-IgG and secondary antibodies. The signal trace returned to the baseline after washed with PBS solution, and the fiber biosensor could be used for next detection. 

Under optimized conditions, a whole process of IgG detection was carried out as follows. First, the RBD modified biosensor was embedded into sample cell as biorecognition element. Then, sample (100 μL) containing various concentrations of IgG was introduced into sample cell and incubated for 7 min. During this period, IgG binds to the optical fiber surface through specific antigen-antibody reaction. After were rinsed to remove excess IgG with PBS buffer, 100 μL fluorescent labeled secondary antibody was introduced and reacted for 7 min. In this stage, 

To evaluate the feasibility of IgG detection using the OPOCT biosensor, two control experiments were carried out. As can be seen from Fig.2a , when 125 ng/mL S-IgG and fluorescence labeled secondary antibody was sequentially introduced into the biosensor, the fluorescence intensity was by far higher than that of only fluorescence labeled secondary antibody. The measured fluorescence intensities were displayed as Fig.S2a . To further verify these results, the fiber biosensors were also characterized by the confocal microscope (Nikon A1, Japan, 638 nm) (Fig.2b) .

Results showed that no fluorescence was observed for the original biosensor modified with RBD (Left in Fig.2b ). When only secondary antibody was introduced over the fiber biosensor surface, a little fluorescence was observed due to non-specific adsorption (Middle in Fig.2b ). With 125 ng/mL IgG, a clear fluorescence image with high brightness was observed after the S-IgG and the fluorescence-labeled secondary antibody were sequentially incubated with biosensor (Right in Fig.2b ). The intensities of the confocal microscope images were consistent with the results of OPOCT sensor (Fig.S2b ). All of these results confirmed that the S-IgG was successfully immobilized on the fiber biosensor surface, and the fluorescence signal detected by the OPOCT originated from the specific binding between RBD and S-IgG. Based on the sandwich immunoassay mechanism, the S-IgG could be quantitatively detected by the OPOCT. 

To improve the detection performance of S-IgG, several detection conditions, including the incubation time between S-IgG antibodies and RBD, the reaction time between secondary antibodies and S-IgG, and the secondary antibodies concentration, were optimized. First, the effect of the incubation time between S-IgG antibodies and RBD was investigated. As shown in Fig. 3a , the fluorescence intensity increased over the incubation time when the incubation time was less than 9 min. This should contribute to the more S-IgG bound with RBD immobilized on the fiber biosensor, thus allowing the more fluorescence labeled secondary antibody to bind with S-IgG and the more fluorescence molecules to be excited. However, the longer incubation time did not further increase the fluorescence intensity. Next, the reaction time between secondary antibodies and S-IgG was optimized. Fig.3b shown that the fluorescence intensity rapidly increased and gradually reached a plateau. To consider the fluorescence intensity and detection time, the incubation time of both secondary antibodies and S-IgG was chosen as 7 min. Finally, the optimization of secondary antibody concentration was performed, and 0.5, 1.0, and 2.0 μg/mL secondary antibody were tested (Fig.3b) . Results showed that higher concentration of secondary antibodies indeed improved the fluorescence signal of S-IgG detection,, whose concentrations were 125 and 250 ng/mL. A sensitivity index (ε) was introduced to determine the optimal concentration. The sensitivity index was defined as ε=(S2-S1)/S2, where S1 and S2 are the fluorescence signal of 125 ng/mL and 250 ng/mL IgG, respectively. High value of ε is conducive to sensitive determination of analyte and is favorable to achieve 0.30. For these three concentrations, the sensitivity indexes were evaluated to be 0.42, 0.25 and 0.27 when the secondary antibody concentrations were 0.5, 1, and 2 μg/mL, respectively. To select the most suitable concentration, the ε should be as high as possible to realize a better sensitivity. Therefore, 0.5 μg/mL AF680-labeled secondary antibody were chosen as the optimal concentration for subsequent IgG measurements. In J o u r n a l P r e -p r o o f addition, the lower concentration secondary antibody can also reduce the reagent consumption thus reducing the testing cost.

The quantification detection of S-IgG was carried out under optimal conditions using the OPOCT. Fig. 4a showed (Table S1 ). Compared with the reported works, our method can achieve quantitative detection of IgG with high sensitivity (LOD=12.5 ng/mL) and relatively short assay time (about 25 min). Moreover, the device is portable and cheaper, and the reusability of fiber biosensor can effectively reduce the cost of testing. Our method is expected to provide a powerful tool for the existing COVID-19 serological assays.

J o u r n a l P r e -p r o o f Due to the complication of serum components (e.g., albumins, polypeptides and globulins), they may affect the interaction between antibody and antigen [28] . Dilution has become an effective method to reduce the matrix effect of the serum on the immunoassay of the clinical samples [28] .

We investigated the matrix effect of serum on the S-IgG detection based on sandwich immunoassay principle. 50 ng/mL and 100 ng/mL S-IgG were spiked in PBS solution, original serum, and various diluted serums, respectively. These samples were detected using the OPOCT according to above described method. As shown in Fig. 5b , the fluorescence intensities of all samples were similar when the S-IgG concentration was 50 ng/mL or 100 ng/mL, respectively. The serum matrix had no significant influence on the binding between S-IgG and RBD, even for the original serum samples.

Therefore, the serum sample can be directly detected using the OPOCT and RBD modified bioprobe without dilution, which benefits to simplify the detection procedure and save the detection time. 

Most of the existing S-IgG rapid on-site immunoassay methods (e.g. LFIA) are disposable. For clinical biomedical analyses, the parallel detection of samples is important to improve the accuracy.

Thus, compared with disposable biosensing method, using the same sensor to complete parallel analysis of samples can reduce the difference between batches, ensure the repeatability of the results and also save the detection cost. Herein, we investigated reusability of RBD modified fiber bioprobe. Because the regeneration solution is generally harsh (strong acid or base), this may damage the activity of biorecognition molecules immobilized onto the biosensor surface. The SDS solution J o u r n a l P r e -p r o o f (0.5%, pH =1.9) was employed to reuse the fiber bio-probe. To evaluate the reusability of fiber bioprobe, the effect of SDS solution on the activity of RBD was initially investigated. The RBD modified fiber bio-probe was repeatedly washed by the SDS solution according to the S-IgG detection procedure. The RBD activity was tested using the OPOCT after washed 5, 10, 15, and 20 times, respectively. As shown in Fig. 6a , after the fiber bio-probe was washed 10 times, the detectable fluorescence intensity had no significant decrease, indicating that the RBD immobilized on the fiber bio-probe surface still kept a high binding affinity with the S-IgG and a good tolerability for SDS regeneration solution. However, more washed times could reduce the binding affinity.

To reuse the fiber bio-probe, the S-IgG and fluorescence labeled secondary antibody bound to the fiber bio-probe surface should completely be removed by the SDS solution. Therefore, multiple immunoassay cycles of S-IgG were performed to verify regeneration performance. As illustrated in Fig. 6b , the RBD could maintain high binding capability with the S-IgG and the fluorescence intensity had no significant decrease after 8 th immunoassay cycles, and the regenerated fiber bioprobe had still few nonspecific adsorptions after 10 th immunoassay cycles. However, with continually increasing the immunoassay times, the detectable fluorescence intensity gradually decreased. The regenerated biosensor surface was also observed using confocal microscope (Nikon A1, Japan) after 5, 10, 15, and 20 times regenerations (Fig.S4) . The amount of the residual fluorescence labeled secondary antibodies on the fiber bio-probe surface increased with increasing immunoassay cycles. Therefore, the prepared fiber bio-probe could be reused about eight immunoassay cycles. For more immunoassay cycles, the activity loss of RBD and incomplete elution of S-IgG/second antibody complex might result in the poor performance. We also tested the regeneration performance for SARS-CoV-2 IgG antibody detection in total serum samples. The results were shown as Fig.S5 . The fiber biosensor also maintained a good detective performance after repeated use for 7 times, which was similar with the detection results in PBS buffer. This result further proved that our method was not interfered by the serum matrix. Increasing the reusability of fiber bio-probe will be the focus of our next research because it can effectively increase the accuracy of detection and reduce the detection cost.

J o u r n a l P r e -p r o o f 

To evaluate reliability of the proposed method, a commercial ELISA kit was obtained and a series of S-IgG concentration were measured from 0 to 2000 ng/mL (Fig.S6) . The ELISA exhibited a linear detection range from 3.66 to 29.38 ng/mL, which is lower but narrower than this study. The difference mainly came from the shorter incubation times compared to ELISA. For ELISA, the incubation time for IgG to RBD and HRP-conjugated second antibodies to IgG were 45 and 30 minutes respectively, while the time was both 7 minutes in our assay. With shorter incubation time, the antibodies could not bind so sufficiently with the immobilized RBD in the binding process, so the detection concentration was higher for our assay. Both methods were used to detect the actual samples. For OPOCT biosensor, the recovery was from 67.78%-125.59% with RSD value within 18.37% when the spiked concentrations were of 100, 250, and 500 ng/mL (Table S2) . For ELISA, when the spiked concentrations of 5, 25 and 50 ng/mL, the recovery was in the range of 71.10-100.5% and the RSD value was within 6.61% (Table S3) . As can be seen, the two methods showed good reliability in their respective linear range, and our method has wider detection range and shorter detection cycle.

To further verify the performance of serum antibody tests, the proposed method had been applied successfully in the IgG antibodies detection after two doses vaccine (Sinopharm, COVID-19). Finger-prick blood samples were collected before and after vaccination from volunteers.

Considering the small volume of finger-prick blood samples, the subsequent detection was carried out with 20 times dilution. Two vaccine recipients were selected and the blood sample from 0-5 weeks were analyzed (Fig.S7 ). Before vaccination, no antibody was detected. After 7 days, a very low amount of IgG antibody was detected in vaccinated 2, and then the antibody concentration gradually increased. After the second injection, the antibody concentration significantly increased, which was similar with those of previous studies [30] . Antibody concentrations were different, but J o u r n a l P r e -p r o o f the relative trend was consistent, which might originate from the individual differences. Therefore, this work can be used to examine the level of SARS-Cov-2 IgG antibody, including COVID-19 patients and vaccinator.

In this study, a rapid and quantitative detection method for anti-SARS-CoV-2 S1 IgG for COVID-19 was developed using OPOCT biosensor. The all-fiber evanescent wave fluorescence platform was employed which exhibits the advantages of compact structure, small size, high sensitivity, and convenient operation. This method realized sensitive quantitative detection of IgG over the range of 12.5-1000 ng/mL. The LOD of 12.5 ng/mL is comparable to other immunoassay for IgG detection, which well satisfies the diagnostic requirements in POC testing. The IgM and other components in serum have no significant effects on IgG detection, and the total serum can be tested directly by the proposed method without dilution. These qualities make it possible to achieve early diagnosis and timely clinical decision-making for COVID-19 with good stability and accuracy.

The evaluation of the regeneration performance indicated that the biosensor can be reused for about 8 times. The characterization results demonstrated that the activity loss mainly arose from the incomplete elution and destruction of surface RBD. The reliability of our method was proved by analyzing serum samples and compared with a commercial ELISA kit. Additionally, the platform can readily be applied to the determination of other biomarkers by using respective specific antibodies. With the above attractive properties, especially high sensitivity and reusability, this method is very suitable and favors a great potential for rapid quantitative POCT for serological analysis of COVID-19.

The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

COVID-19 outbreak: Migration, effects on society, global environment and prevention

Molecular and immunological diagnostic tests of COVID-19: current status and challenges

Detection of COVID-19: A review of the current literature and future J o u r n a l P r e -p r o o f perspectives

Molecular diagnostic technologies for COVID-19: Limitations and challenges

Diagnostic methods and potential portable biosensors for coronavirus disease

The impact of biosensing in a pandemic outbreak: COVID-19

Benefits and limitations of serological assays in COVID-19 infection

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

The important role of serology for COVID-19 control

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Rapid, ultrasensitive and highly specific biosensor for the diagnosis of SARS-CoV-2 in clinical blood samples

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Assay techniques and test development for COVID-19 diagnosis

Current and perspective diagnostic techniques for COVID-19

Nanomaterial labels in lateral flow immunoassays for point-of-care-testing

A sensitive and quantitative prognosis of C-reactive protein at picogram level using mesoporous silica encapsulated core-shell upconversion nanoparticle based lateral flow strip assay

5G-enabled ultra-sensitive fluorescence sensor for proactive prognosis of COVID-19

Development of spike protein-based fluorescence lateral flow assay for the simultaneous detection of SARS-CoV-2 specific IgM and IgG

Recent development of fiber-optic chemical sensors and biosensors: mechanisms, materials, micro/nano-fabrications and applications

Recent advances in fiberoptic evanescent wave sensors for monitoring organic and inorganic pollutants in water

Reusable split-aptamer-based biosensor for rapid detection of cocaine in serum by using an all-fiber evanescent wave optical biosensing platform

Reusable optofluidic point-of-care testing platform with lyophilized specific antibody for fluorescence detection of cholylglycine in serum

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Portable and automated fluorescence microarray biosensing platform for on-site parallel detection and early-warning of multiple pollutants

Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients'B Cells

Human neutralizing antibodies elicited by SARS-CoV-2 infection

COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by a quantitative and sensitive immunoassay

Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detector

Engineering luminescent biosensors for point-ofcare SARS-CoV-2 antibody detection

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing

A microflow cytometry-based agglutination immunoassay for point-of-care quantitative detection of SARS-CoV-2 IgM and IgG

ACKNOLEDGEMENTS This work was supported by the National Natural Science Foundation of China (21675171) and the Outstanding Innovative Talents Cultivation Funded Programs 2020 of Renmin University of China

An optofluidic point-of-care testing fluorescence (OPOCT) biosensor was proposed for quantitative detection of anti-SARS-CoV-2 IgG antibody

Accurate detection of anti-SARS-CoV-2 IgG in serum was realized with simple dilution using the OPOCT biosensor

Reliable results were obtained from multiple antibody immunoassays because of the reusable bio-probe

J o u r n a l P r e -p r o o f

☒The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f